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Abstract
Background: Serum 25-hydroxyvitamin D3 levels are generally lower in chronic hepatitis C patients than in healthy
individuals. The purpose of this study is to clarify the factors which affect serum 25-hydroxyvitamin D3 levels using
data obtained from Japanese chronic hepatitis C patients.
Methods: The subjects were 619 chronic hepatitis C patients. Serum 25-hydroxyvitamin D3 levels were measured
by using double-antibody radioimmunoassay between April 2009 and August 2014. Serum 25-hydroxyvitamin D3
levels of 20 ng/mL or less were classified as vitamin D deficiency, and those with serum 25-hydroxyvitamin D3
levels of 30 ng/mL or more as vitamin D sufficiency. The relationship between patient-related factors and serum
25-hydroxyvitamin D3 levels was analyzed.
Results: The cohort consisted of 305 females and 314 males, aged between 18 and 89 years (median, 63 years).
The median serum 25-hydroxyvitamin D3 level was 21 ng/mL (range, 6–61 ng/mL). On the other hand, the median
serum 25-hydroxyvitamin D3 level in the healthy subjects was 25 ng/mL (range, 7–52), being significantly higher
than that those in 80 chronic hepatitis C patients matched for age, gender, and season (p = 1.16 × 10−8). In
multivariate analysis, independent contributors to serum 25-hydroxyvitamin D3 deficiency were as follows: female
gender (p = 2.03 × 10−4, odds ratio = 2.290, 95 % confidence interval = 1.479–3.545), older age (p = 4.30 × 10−4,
odds ratio = 1.038, 95 % confidence interval = 1.017–1.060), cold season (p = 0.015, odds ratio = 1.586, 95 %
confidence interval = 1.095–2.297), and low hemoglobin level (p = 0.037, odds ratio = 1.165, 95 % confidence
interval = 1.009–1.345). By contrast, independent contributors to serum 25-hydroxyvitamin D3 sufficiency were
male gender (p = 0.001, odds ratio = 3.400, 95 % confidence interval = 1.635–7.069), warm season (p = 0.014, odds
ratio = 1.765, 95 % confidence interval = 1.117–2.789) and serum albumin (p = 0.016, OR = 2.247, 95 % CI = 1.163–4.342).
Conclusions: Serum 25-hydroxyvitamin D3 levels in chronic hepatitis C Japanese patients were influenced by gender,
age, hemoglobin level, albumin and the season of measurement.
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Background
Chronic hepatitis C (CHC) affects 170 million people
worldwide [1]. Liver cirrhosis and hepatocellular carcin-
oma (HCC) are known to develop if CHC is left un-
treated; therefore, hepatitis C virus (HCV) needs to be
eliminated from CHC patients [2]. In recent years, re-
markable progress has been made in the treatment of
CHC. The sustained virologic response (SVR) rate in
patients with genotype 1 CHC, which is difficult to treat,
has been reported to improve to approximately 80 % by
pegylated interferon (IFN)/ribavirin combined with pro-
tease inhibitors [3–5]. Furthermore, direct-acting anti-
viral agents such as NS3/4A protease inhibitors, NS5B
polymerase inhibitors, and NS5A inhibitors have a
strong therapeutic effect by directly inhibiting the prolif-
eration of HCV, and thus is expected to be the main-
stream treatment for CHC in the future [6–9].
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The classical active form of vitamin D plays a major
role in increasing the serum calcium concentration by
promoting absorption of calcium from the intestinal
tract or increasing bone resorption [10]. In recent years,
reports have been accumulating on the involvement of
serum vitamin D level in various diseases. The mortality
from cardiovascular disease is low in patients with high
serum vitamin D levels [11]. Also, low serum vitamin
levels have been related to the incidence of various can-
cers, including colon cancer [12], breast cancer [13], and
prostate cancer [14, 15]. Low serum vitamin D levels are
suggested to aggravate insulin resistance [16], which can
be improved with vitamin D supplements [17]. Low
serum vitamin D levels are also observed in patients
who have undergone gastrectomy, suggesting that the
reduced level is causally related to insufficient vitamin D
absorption or intake [18, 19]. Serum vitamin D levels have
been also reported to be closely correlated with CHC.
Vitamin D is synthesized mainly in the skin as well as
being ingested from food. This synthesis of vitamin D in
the skin declines with age. With ultraviolet irradiation,
7-dehydrocholesterol in the skin is converted to pre-
vitamin D3. Position 25 is hydroxylated in the liver and
metabolized to 25-hydroxyvitamin D3. Position 1α is hy-
droxylated in the kidneys to form active 1,25-dihydroxy-
vitamin D3, which binds to vitamin D receptors. In a
related pathway, vitamin D is converted into various
metabolites, which bind to vitamin D-binding protein
and circulate stably in blood. Among the circulating
metabolites, 25-hydroxyvitamin D3 is the most stable
and has a long half-life in blood. Therefore, the serum
25-hydroxyvitamin D3 level is often used as a repre-
sentative value for the serum vitamin D level. Serum
25-hydroxyvitamin D3 levels are lower in CHC pa-
tients than in healthy individuals, and decrease with
the progression of liver fibrosis [20, 21]. In IFN-based
therapy for CHC, serum vitamin D levels influence
the therapeutic efficacy [20, 22–24].
Serum 25-hydroxyvitamin D3 levels are thought to differ
by country and region. For instance, they tend to be lower
at high latitudes. A study of healthy people in Norway
showed that the mean serum 25-hydroxyvitamin D3 level
was approximately 20 ng/ml, and that the percentage of
subjects with sufficient serum 25-hydroxyvitamin D3
levels was only 9 % [25]. However, the deficiency of serum
25-hydroxyvitamin D3 level cannot be explained by the
difference in latitudes alone. In fact, the serum 25-
hydroxyvitamin D3 level was reported to be lower than
30 ng/mL in more than 50 % of young people in Hawaii
despite sufficient exposure to sunlight [26]. The discrep-
ancy may be attributable to racial difference and dietary
lifestyle.
There have been few studies concerning factors corre-
lated with serum 25-hydroxyvitamin D3 levels for CHC
patients in East Asia, where there are four distinct sea-
sons in temperate latitudes. The purpose of this study
was to investigate serum 25-hydroxyvitamin D3 levels
and to analyze factors influencing these levels using data
obtained Japanese chronic hepatitis C patients.
Methods
Subjects
The subjects were CHC patients who visited the Nippon
Medical School Chiba Hokusoh Hospital, Nippon
Medical School, Tokushukai Chiba Hospital, Jikei
University School of Medicine Katsusika Medical
Center, Jikei University School of Medicine Kashiwa
Hospital, Ibaraki Central Hospital, Tokyo Metropolitan
Bokutoh Hospital, Tokyo Medical University Ibaraki
Medical Center, Machida Municipal Hospital, and Saiseikai
Yokohamashi Tobu Hospital between April 2009 and
August 2014. All were positive for HCV RNA based
on real-time polymerase chain reaction (PCR)-based
assay. The analysis was exclusively done on candidates
for antiviral treatment, and thus was limited to those
infected with HCV genotype 1, who are difficult to
treat and account for a large portion of CHC patients
in Japan. To reduce the influence of patient state on
serum vitamin D levels, only patients with a score of
0 or 1 based on the Eastern Cooperative Oncology
Group Performance Status criteria were selected as
subjects. Exclusion criteria were hepatitis B surface
antigen positivity, human immunodeficiency virus
antigen positivity, the presence of other chronic liver
diseases such as autoimmune hepatitis or primary bil-
iary cirrhosis, decompensated cirrhosis, taking drugs
and/or supplements containing vitamin D, and being
under anti-cancer treatment. Eighty healthy volunteers
recruited from April 2009 and August 2014, matched
for gender, age and season, were enrolled as controls.
The study protocol followed the ethical guidelines
established in accordance with the 2008 Declaration of
Helsinki and was approved by the Ethics Committee of
Nippon Medical School Chiba Hokusoh Hospital. All pa-
tients provided written informed consent.
Laboratory methods
Hematological and biochemical tests were performed,
and clotting factors and tumor markers were measured
for all patients. Serum 25-hydroxyvitamin D3 levels were
measured by a double-antibody radioimmunoassay kit
(SRL Inc., Tokyo, Japan). Serum 25-hydroxyvitamin D3
levels of 20 ng/mL or less were classified as vitamin D
deficiency, those of 21–29 ng/mL as vitamin D insuffi-
ciency, and those with serum 25-hydroxyvitamin D3
levels of 30 ng/mL or more as vitamin D sufficiency
[27]. Cases for which serum 25-hydroxyvitamin D3 levels
were measured between May and October, a period
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when there are long hours of daylight, were defined as
the “warm season” group, and those between November
and April, a period when there are short hours of day-
light, were defined as the “cold season” group. HCV
RNA levels were measured by the real-time PCR method
(COBAS® AmpliPrep; Roche Diagnostics, Tokyo). Gene
mutations in the core amino acids 70 and 91, and NS5A
regions (interferon sensitivity determining region; ISDR)
of the HCV genome were determined using the direct
sequencing method. Core amino acid 70 was defined as
wild type (arginine) or mutant type (glutamine or histi-
dine), and core amino acid 91 was defined as the wild
type (leucine) or the mutant type (methionine). Amino
acid mutations in the ISDR were defined as wild type
(0, 1) or mutant type (2 or more). Genomic DNA was
extracted from whole blood using a DNA isolation kit on
a MagNA Pure LC Instrument (Roche Diagnostics, Basel,
Switzerland). The single nucleotide polymorphism (SNP)
rs8099917 near the interleukin (IL) 28B gene was deter-
mined by real-time detection PCR using the TaqMan®
SNP genotyping assay (Applied Biosystems, Foster City,
CA). The rs8099917 genotype was classified into two cat-
egories: TT and non-TT (TG or GG). The Fib-4 index was
calculated as an indicator of fibrosis [28]. A Fib-4 index of
greater than 3.25 was defined as advanced liver fibrosis.
Statistical analyses
Fisher’s exact test and Mann–Whitney U-test were
performed to compare serum 25-hydroxyvitamin D3
levels between the two groups. Logistic regression
analysis for univariate comparison was performed to
investigate whether each factor influenced the serum
25-hydroxyvitamin D3 level. Multiple logistic regression
analysis was performed to identify significant, independent
factors that influenced serum 25-hydroxyvitamin D3
levels. All statistical analyses were performed using IBM
SPSS version 17.0 (IBM Japan, Tokyo). The level of statis-
tical significance was set at p < 0.05.
Results
Background
The 619 subjects consisted of 305 females (49.7 %) and
314 males (50.7 %), aged between 18 and 89 years
(median, 63 years; Table 1). The median serum 25-
hydroxyvitamin D3 level was 21 ng/mL (range, 6–61 ng/
mL). Serum 25-hydroxyvitamin D3 levels in 257 patients
(41.5 %) were measured during the warm season. The me-
dian Fib-4 index, an indicator of fibrosis degree in the
liver, was 3.12 (range, 0.45–15.97). The number of patients
with a Fib-4 index of greater than 3.25, indicative of
advanced liver fibrosis [28], was 282 (45.6 %). The per-
centages of subjects with vitamin D deficiency, insuffi-
ciency, and sufficiency were 47.0 % (291 of 619 patients),
36.7 % (227 of 619 patients), and 16.3 % (101 of 619
patients), respectively (Fig. 1). The IL28B SNP genotype
rs8099917, the most important determinant of the re-
sponsiveness to interferon-based therapy, was TT in
356 patients (57.5 %). On the other hand, the median
serum 25-hydroxyvitamin D3 level in the healthy sub-
jects was 25 ng/mL (range, 7–52), being significantly
higher than that those in 80 CHC patients matched
for age, gender, and season (p = 1.16 × 10−8). The percent-
ages of healthy subjects with vitamin D deficiency, insuffi-
ciency, and sufficiency were 33.7 % (27 of 80 patients),
40.0 % (32 of 80 patients), and 26.3 % (21 of 80 patients),
respectively (Fig. 1).
Table 1 Baseline characteristics of 619 patients with chronic
hepatitis C
Factors n = 619
Gender (M/F) 314/305
Age (y.o) 63 (18–89)
Body weight (kg) 59.8 (33.0–115.8)
BMI (kg/m2) 23.86 (15.48–37.81)
Fib-4 Index 3.12 (0.45–15.97)
Season (Month) (11-4/5-10/NA) 361/257/1
Leukocytes (/mm3) 4700 (1800–16,100)
Hemoglobin (g/dL) 13.7 (7.5–17.7)
Platelets (×103/mm3) 151 (31–407)
AST (U/L) 48 (13–398)
ALT (U/L) 48 (10–362)
gamma-GT (U/L) 43 (8–1031)
Alpha-fetoprotein (ng/mL) 5.7 (3.6–754.7)
Total bilirubin (mg/dL) 0.7 (0.2–2.8)
Serum albumin (g/dL) 4.1 (2.5–5.1)
Total-cholesterol (mg/dL) 166 (55–310)
LDL-cholesterol (mg/dL) 94 (21–204)
HDL-cholesterol (mg/dL) 51 (8–149)
Serum creatinine (mg/dL) 0.70 (0.32–11.87)
HCV RNA (logIU/mL) 6.4 (1.2–7.8)
Fasting plasma glucose (mg/dL) 102 (65–342)
HOMA-R 2.0 (0.3–84.7)
25-hydroxyvitamin D3 (ng/ml) 21 (6–61)
Prothrombin time (%) 90.7 (14.5–177.6)
ISDR (0,1/others/NA) 349/158/112
Core amino acid 70 (wild type/mutant type/NA) 291/217/111
IL28B genotype rs8099917 (TT/non-TT/NA) 356/242/21
Hepatocellular carcinoma (presence/absence) 44/575
Categolic values are given as number. Continuous variable are given as
median (range) BMI body mass index, AST aspartate aminotransferase, ALT
alanine aminotransferase, gamma-GT gamma-glutamyltaransferase, LDL
low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol,
HOMA-R homeostasis model assessment ratio, ISDR interferon sensitivity
determining region, IL28B interleukin 28B
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Relationship between serum 25-hydroxyvitamin D3 levels
and other factors
With regard to the season, a significant difference in serum
25-hydroxyvitamin D3 was observed between May–
October and November–April: when the median level was
22 ng/ml [interquartile range (IQR), 17–28 ng/mL] and
20 ng/mL (IQR, 15–25 ng/mL), respectively (p = 6.36 ×
10−4; Fig. 2a). As for gender, serum 25-hydroxyvitamin D3
levels in male patients (median, 24 ng/mL; IQR, 18–
29 ng/mL) were significantly higher than those in female
patients (median, 19 ng/mL; IQR, 15–24 ng/mL) (p =
4.02 × 10−10; Fig. 2b).
In the present study, the Fib-4 index was used to
evaluate the degree of hepatic fibrosis. The serum 25-
hydroxyvitamin D3 level inversely decreased with an
increase in the Fib-4 index, though the negative cor-
relation between them was weak (Fig. 3). Interest-
ingly, there were few patients with a Fib-4 index of
7.0 or more and serum 25(OH) D3 level of 30 ng/mL
or more (vitamin D sufficiency). Conversely, 459 of
609 (75.4 %) patients showed a Fib-4 index of less
than 7.0 and serum 25-hydroxyvitamin D3 level of
less than 30 ng/mL. When patients were categorized
into two groups based on the Fib-4 index (of 3.25,
which is predictive of advanced liver fibrosis), the median
serum 25-hydroxyvitamin D3 level was 20 ng/ml (IQR,
16–26 ng/mL) in those with a Fib-4 index of greater than
3.25 and 21 ng/ml (IQR, 17–27 ng/mL) in those with a
Fib-4 index of 3.25 or less (p = 7.52 × 10−3).
In univariate analysis, vitamin D deficiency was signifi-
cantly influenced by the following factors: female gender
[p = 5.49 × 10−7, odds ratio (OR) = 2.316, 95 % confidence
interval (CI) = 1.667–3.217], high Fib-4 index (p = 0.031,
OR = 1.076, 95 % CI = 1.007–1.150), cold season (p = 0.013,
OR: 1.520, 95 % CI: 1.092–2.114), low hemoglobin value
(p = 3.64 × 10−5, OR: 1.249, 95 % CI: 1.123–1.387), low total
cholesterol (p = 0.012, OR: 1.006, 95 % CI: 1.001–1.012),
low serum albumin (p = 0.001, OR: 1.898, 95 % CI: 1.278–
2.817) and low prothrombin time (p = 0.042, OR:
1.011, 95 % CI: 1.000–1.022). In multivariate analysis, fe-
male gender (p = 2.03 × 10−4, OR = 2.290, 95 % CI = 1.479–
Fig. 1 Distribution of serum 25-hydroxyvitamin D3 level in chronic
hepatitis C patients and healthy subjects. Serum 25-hydroxyvitamin
D3 levels of 20 ng/mL or less were defined as vitamin D deficiency,
those of 21–29 ng/mL were defined as vitamin D insufficiency, and
those with serum 25-hydroxyvitamin D3 levels of 30 ng/mL or more
were defined as vitamin D sufficiency
Fig. 2 a) We defined the cases that serum 25-hydroxyvitamin D3 levels were measured between May and October as warm season, and the cases
that serum 25-hydroxyvitamin D3 levels were measured between November and April as cold season. b) Serum 25-hydroxyvitamin D3 level
according to season and gender
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3.545), older age (p = 4.30 × 10−4, OR = 1.038, 95 % CI =
1.017–1.060), cold season (p = 0.015, OR = 1.586, 95 %
CI = 1.095–2.297), and low hemoglobin level (p = 0.037,
OR = 1.165, 95 % CI = 1.009–1.345) were significantly in-
dependent factors (Table 2).
Univariate analysis of factors contributing to serum
25-hydroxyvitamin D3 sufficiency identified the factors
of male gender (p = 2.43 × 10−7, OR = 3.576, 95 % CI =
2.205–5.802), high body weight (p = 0.004, OR = 1.024,
95 % CI = 1.008–1.040), high Fib-4 index (p = 0.016,
OR = 0.877, 95 % CI = 0.788–0.976), warm season (p =
0.016, OR = 1.694, 95 % CI = 1.104–2.600), high gamma-
glutamyl transpeptidase (p = 0.029, OR = 1.002, 95 %
CI = 1.000–1.005) and high serum albumin (p = 0.004,
OR = 2.373, 95 % CI = 1.295–3.989). Multivariate ana-
lysis identified male gender (p = 0.001, OR = 3.400, 95 %
CI = 1.635–7.069), warm season (p = 0.014, OR = 1.765,
95 % CI = 1.117–2.789) and serum albumin (p = 0.016,
OR = 2.247, 95 % CI = 1.163–4.342) as independent
factors (Table 3). Neither substitution of core amino
Fig. 3 Relationship between serum 25-hydroxyvitamin D3 level and FIB-4 Index value. There were few patients with Fib-4 index of 7.0 or more
and serum 25-hydroxyvitamin D3 level of 30 ng/mL or more. Conversely, 459 of 609 patients showed Fib-4 index of less than 7.0 and serum
25-hydroxyvitamin D3 level of less than 30 ng/mL
Table 2 Univariate and multivariate logistic regression analyses of factors associated with serum 25-hydroxyvitamin D3 levels deficiency
in the 619 patients
Univariate Multivariate
Factors Category OR 95 % CI p value OR 95 % CI p value
Gender Female 2.316 1.667–3.217 5.49 × 10−7 2.290 1.479–3.545 2.03 × 10−4
Age By 1 year up 1.014 0.999–1.030 0.073 1.038 1.017–1.060 4.30 × 10−4
Fib-4 Index By 0.1 up 1.076 1.007–1.150 0.031
Season Cold season 1.520 1.092–2.114 0.013 1.586 1.095–2.297 0.015
Hemoglobin By 1 g/dL down 1.249 1.123–1.387 3.64 × 10−5 1.165 1.009–1.345 0.037
Total-cholesterol By 1 mg/dL down 1.006 1.001–1.012 0.012
Albumin By 0.1 down 1.898 1.278–2.817 0.001
Prothrombin time By 1 % down 1.011 1.000–1.022 0.042
Serum 25-hydroxyvitamin D3 levels of 20 ng/ml or less were defined as vitamin D deficiency. Multivariate analysis was performed with factors associated with
serum 25-hydroxyvitamin D3 levels deficiency by univariate analysis (p < 0.10). We defined the cases that serum 25-hydroxyvitamin D3 levels were measured
between November and April as cold season
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acid 70 and 91 nor IL28B genotype, which has a strong
impact on the outcome of IFN-based antiviral therapy,
influenced the serum 25-hydroxyvitamin D3 level.
Discussion
In recent reports from various countries, the level of
serum vitamin D is closely involved in the pathology of
CHC and the response to IFN-based treatment of the
infection. In Spain, the mean serum 25-hydroxyvitamin
D3 level was 30.2 ng/mL in 32 CHC patients [29]. In
Turkey, it was 14.16 ng/mL in 105 patients with chronic
hepatitis B or C and even lower in postmenopausal fe-
male patients (11.32 ng/mL) [30]. In Italy, 73 % of 197
CHC patients showed insufficient levels of serum 25-
hydroxyvitamin D3. In the Italian cohort, female gender
was an independent factor associated with vitamin D
deficiency [20]. Among 503 healthy subjects, the lowest
serum 25-hydroxyvitamin D3 level was noted in Asians
[31]. The present study was the first to investigate serum
vitamin D levels and the influencing factors in a large-
scale cohort of more than 600 genotype 1b CHC pa-
tients in Japan, which is located in Far East and has four
distinct seasons.
Vitamin D is closely involved in host immunity. Vita-
min D enhances the antigen-presenting ability of den-
dritic cells and increases the phagocytic capacity against
external antigens [32]. Abnormal differentiation of mac-
rophages, on which vitamin D receptors are expressed as
part of the innate immune system, is observed in vitamin
D-deficient mice [33]. In the acquired immune system,
vitamin D receptors are expressed in mature T-cells and
B-cells [34], and T-cell receptor signals are regulated by
1,25-dihydroxyvitamin D3 via vitamin D receptors [35].
Vitamin D also elevates the cytotoxic activity of natural
killer cells [36] and has an inflammation-inhibiting ac-
tion [37–39]. The incidence of tuberculosis and other
infectious diseases was also reported to increase with
decreased serum vitamin D levels [40].
As mentioned above, vitamin D may promote the
elimination of HCV by its immunopotentiating effect.
However, several studies recently reported the direct
anti-HCV effect of vitamin D. In an in vitro study using
the Huh7.5 human hepatocyte cell line, the addition of
vitamin D3 and its metabolite 1,25-dihydroxyvitamin D3
decreased HCV secretion into the cell culture medium
[41]. Furthermore, the concomitant administration of
IFN synergistically enhanced the effect of 1,25-dihy-
droxyvitamin D3 [41]. In another in vitro study, 25-
hydroxyvitamin D3 had direct anti-HCV effects by
suppressing the formation of infectious HCV particles
[42]. In a clinical trial involving 42 chronic hepatitis
C patients, combination of 1(OH) vitamin D3 with
pegylated IFN/ribavirin therapy augmented an early
decrease in the HCV load. This effect may be ascribed to
a decrease in the serum-inducible protein-10 level
and enhancement of the type 1 T helper cell response
[43]. Among 468 CHC patients, the decreased 25-
hydroxyvitamin D level and CYP27B1-1260 promoter
SNP were associated with the decreased efficacy of
IFN-α-based therapy [44]. Among 42 post-liver trans-
plant CHC patients, vitamin D supplementation was
suggested to improve the antiviral treatment outcome
[45]. Among 15 elderly CHC patients who received
IFN-based therapy, administration of alfacalcidol, an
active form of vitamin D, increased the SVR rate, particu-
larly in female patients [46]. Among 134 HCV genotype 1
cirrhotic patients, the serum 25-hydroxyvitamin D3 level
was an independent factor contributing to SVR with pegy-
lated IFN/ribavirin therapy [23]. In addition, the serum
25-hydroxyvitamin D3 level influenced the SVR rate even
in pegylated IFN/ribavirin therapy combined with telapre-
vir, a first-generation protease inhibitor. The impact was
particularly notable in patients with unfavorable IL28B
non-TT (rs8099917) genotype [24].
The absence of a vitamin D effect on antiviral treat-
ment for CHC has been reported by some studies. One
Table 3 Univariate and multivariate logistic regression analyses of factors associated with ≥30 ng/ml of serum 25-hydroxyvitamin D3
levels in the 619 patients
Univariate Multivariate
Factors Category OR 95 % CI p value OR 95 % CI p value
Gender Male 3.576 2.205–5.802 2.43 × 10−7 3.400 1.949–5.918 1.60 × 10−5
Body weight (kg) By 1 kg up 1.024 1.008–1.040 0.004
Fib-4 Index By 0.1 down 0.877 0.788–0.976 0.016
Season Warm season 1.694 1.104–2.600 0.016 1.765 1.117–2.789 0.015
gamma-GT (U/L) By 1 U/ml up 1.002 1.000–1.005 0.029
Albumin (mg/dL) By 0.1 up 2.273 1.295–3.989 0.004 2.247 1.163–4.342 0.016
HOMA-R By 0.1 up 0.819 0.668–1.003 0.054
Multivariate analysis was performed with factors significantly associated with ≥30 ng/ml of serum 25-hydroxyvitamin D3 levels by univariate analysis (p < 0.10). We
defined the cases that serum 25-hydroxyvitamin D3 levels were measured between May and October as warm season. gamma-GT gamma-glutamyltaransferase
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reported that the SVR rate did not differ according to
the serum vitamin D level, whereas the complete early
viral response rate was associated with it [47]. Another
study reported that vitamin D supplementation for CHC
patients with genotype 1b significantly increased the
viral response rate at 24 weeks of treatment but did not
significantly (marginally) raise the SVR rate [48]. Taken
together, the pros and cons of vitamin D suggest that
vitamin D supplementation in IFN-based antiviral ther-
apy for CHC might modify the virologic response during
the early treatment phase and could have an impact on
treatment outcome in some groups of the patient
population.
Some factors appear to have an impact on serum vita-
min D levels. In this study, serum vitamin D levels were
correlated inversely with serum ALT levels, suggesting
the anti-inflammatory action of vitamin D [27, 37–39].
In fact, a previous study suggested that alfacalcidol sup-
plementation could decrease serum ALT levels in CHC
[46]. The progression of liver fibrosis is negatively related
with the serum vitamin D level [20, 22, 44]. Our previous
study showed that the median 25-hydroxyvitamin D3 level
in 134 cirrhotic patients who received pegylated IFN/riba-
virin therapy was 21 ng/mL, which was lower than that in
healthy individuals and non-cirrhotic hepatitis C patients
[23]. Interestingly, 1,25-dihydroxyvitamin D3, an active
form of vitamin D, was reported to have anti-proliferative
and anti-fibrotic effects on hepatic fibrosis [49]. In this
study, patients with high Fib-4 index values had low
serum vitamin D levels, bearing out a previously reported
correlation between vitamin D and fibrosis. Of note is that
this study found that almost all patients with a Fib-4 index
of 7.0 or more showed serum vitamin D levels of less than
30 ng/mL (vitamin D insufficiency or deficiency). Con-
versely, the degree of liver fibrosis could be estimated
from the serum level of vitamin D: patients with sufficient
vitamin D levels would express a Fib-4 index of less
than 7.0.
As described in this study, serum vitamin D levels are
lower in elderly and female patients. The vitamin D defi-
ciency in females may arise from unbalanced diets and
nutrition and excess avoidance of ultraviolet light based
recent esthetic trends. The high prevalence of vitamin D
deficiency in Muslim women in the Middle-East [50]
may be caused by their habit of extensively covering
their skin with clothing, which could prevent the pro-
duction of vitamin D. Serum 25-hydroxyvitamin D3
levels also vary depending on the season. One study
from Italy showed that serum 25-hydroxyvitamin
D3levels significantly differed between spring and winter
in 211 chronic hepatitis patients, and that the season
was an independent factor associated with the serum 25-
hydroxyvitamin D3 level. Also in Japan, which has four
distinct seasons, this study re-confirmed that serum
25-hydroxyvitamin D3 levels are lower in samples col-
lected during the cold season. However, monthly serum
levels observed in this study suggested that it might be dif-
ficult to simply divide the four seasons into two groups
(warm vs. cold).
Decreased activity or not going out frequently may
contribute to lower serum vitamin D levels. Specifically,
in elderly female subjects who have anemia and/or
advanced liver fibrosis, reduced sunshine exposure may
result in poor vitamin D synthesis. In deed, it was shown
that seasonal variation in the amount of sunlight expos-
ure influences the serum vitamin D level: a season with
low-level sunshine was an independent factor associated
with a decreased serum vitamin D level, whereas, a sea-
son with more sunshine was the second most important
factor associated with a sufficient serum vitamin D after
sex differences. It was reported that in patients with
advanced liver fibrosis, there was a decreased level of
serum vitamin D. In such patients, active exposure to
sunshine may increase the serum vitamin D level. Thus,
our study suggests that the progression of liver fibrosis
may not influence the serum vitamin D level, depending
on a patient’s environmental factors. We showed another
important reason which an environmental factor gives to
serum vitamin D level. In this study multivariate analysis
of a factor contributing to serum 25-hydroxyvitamin D3
sufficiency identified the factors of warm season as an
independent factor.
There were some limitations in this study. First, the
subjects were limited to HCV genotype 1 patients. In the
participating facilities, most of the patients infected with
minor genotype 2 have already been cured with IFN-
based treatment. Therefore, this study could not clarify
the influence of HCV genotype on the serum 25-
hydroxyvitamin D3 level. Second, patients with decom-
pensated cirrhosis were not included in the study group.
They show even lower levels compared to patients with
compensated cirrhosis. In addition, although we gath-
ered seasonal data on serum vitamin D measurement,
data on the number of hours of sunshine per day were
not available.
Conclusions
In summary, the present study found that serum 25-
hydroxyvitamin D3 levels were deficient in the elderly,
females, and patients with low hemoglobin level.
Serum 25-hydroxyvitamin D3 levels were sufficient in
males and high serum albumin levels. In Japan located in
East Asia, serum 25-hydroxyvitamin D3 levels differed
with the season.
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